Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
- Dr. Utkarsh Acharya answers three more questions about the challenges, sources of pride and frustrations of being a doctor caring for CAR-T patients so early in the therapy’s development
- At the first ERIC meeting in Barcelona, Dr,. Brian Koffman had a chance to interview one of the researchers, Dr. Cameron Turtle, involved his trial in Seattle at the SCCA/Hutch
- I remain cancer free today due a remarkable team of doctors who have dedicated their life to researching and improving the safety and efficacy of CAR-T therapy. This week is the first part of my interview with one of the best young physicians in that field, Dr. Utkarsh H. Acharya. Also this week is my blog post on my great news that there was no detectable CLL in my my bone marrow at my recent 6 month restaging.
- Watch and wait is the classic approach for all newly diagnosed CLL patients, but in the era of new targeted therapies, does it make sense to intervene early in high risk patients. This new trial for early stage high-risk CLL patients will examine that question. Enrollment is open now.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. The CLL Society is launching a program to provide free second opinions for CLL patients who have not had or who are not able to secure such access. Find out more about this program.
Research Results
The CLL Society regularly polls CLL patients for feedback about educational needs, clinical trial participation, treatment status, self-assessed knowledge of CLL, sources of information, and more.
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL